IAA Journal of Applied Sciences 14(1):6-11, 2026. www.iaajournals.org
©IAAJOURNALS ISSN: 2636-7246
https://doi.org/10.59298/IAAJAS/2026/141611 IAAJAS: 141000

Rheumatoid Factor Beyond Rheumatoid Arthritis: Metabolic and Immunologic Implications in Diabetes Mellitus

Mugo Moses H.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Rheumatoid factor (RF), a classic autoantibody directed against the Fc portion of immunoglobulin G (IgG), has long been recognized as a hallmark of rheumatoid arthritis (RA). However, emerging evidence indicates that RF positivity extends far beyond rheumatologic disease and may carry important metabolic and immunologic implications, particularly in diabetes mellitus. The rising global burden of diabetes, including both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), has renewed interest in the role of chronic inflammation and autoimmunity in metabolic dysregulation. RF has been detected in a substantial proportion of diabetic individuals, especially those with long-standing hyperglycemia, microvascular complications, or coexisting autoimmune phenomena. Its presence correlates with oxidative stress, subclinical inflammation, endothelial dysfunction, and altered immunometabolic pathways. Recent studies suggest that RF positivity may predict poor glycemic control, increased cardiovascular risk, and enhanced susceptibility to diabetic complications, independent of traditional risk factors. Moreover, RF may reflect broader immune dysregulation involving B-cell hyperactivity, advanced glycation end-products, molecular mimicry, and chronic antigenic stimulation. This review synthesizes current evidence on the epidemiology, mechanisms, clinical significance, and potential therapeutic implications of RF in diabetes, highlighting its emerging role as a biomarker of systemic immune activation beyond rheumatoid arthritis.

Keywords: Rheumatoid factor, Diabetes mellitus, Autoimmunity, Inflammation, Immunometabolism

INTRODUCTION

Rheumatoid factor (RF) is traditionally associated with rheumatoid arthritis, where it functions as a diagnostic and prognostic marker reflecting underlying B-cell dysregulation and chronic immune activation[1]. Defined as an autoantibody directed against the Fc portion of immunoglobulin G (IgG), RF exists in several isotypes, most commonly IgM, but also IgA and IgG. Although widely regarded as a hallmark of rheumatoid arthritis, RF is not disease-specific[2]. It has been detected in a broad range of conditions, including chronic infections, aging, autoimmune disorders, certain malignancies, and increasingly in metabolic diseases such as diabetes mellitus. The presence of RF in these diverse settings underscores its role as a general indicator of immune perturbation rather than as a marker confined to rheumatologic pathology [3]. Diabetes mellitus is now recognized as a condition that extends beyond metabolic dysfunction to encompass complex immune-inflammatory disturbances. Both type 1 and type 2 diabetes involve interactions among innate immune activation, dysregulated adaptive immunity, oxidative stress, and chronic low-grade inflammation, creating an internal environment that may promote autoantibody formation[4]. As research advances, RF has emerged as a potential marker of this broader immunologic imbalance. Its detection in individuals with diabetes suggests a convergence between metabolic stress and immune activation. This review, therefore, examines RF within the context of diabetes, exploring its epidemiology, mechanistic pathways, and potential implications for disease progression and systemic inflammation[5]. By synthesizing insights from immunology and metabolic research, RF can be appreciated as a lens through which

the inflammatory landscape of diabetes may be better understood.

2. Epidemiology of RF Positivity in Diabetes Mellitus

RF positivity is found in approximately 3 to 5 percent of the healthy population but appears at notably higher frequencies among individuals with diabetes. In type 1 diabetes, reported prevalence ranges from 8 to 20 percent, particularly in patients who exhibit additional autoimmune conditions such as autoimmune thyroid disease or celiac disease, suggesting a clustering of immune abnormalities[6]. In type 2 diabetes, RF positivity has been observed in 10 to 25 percent of patients, with higher rates among those with long-standing hyperglycemia, obesity, or metabolic syndrome. Several studies further indicate that RF levels correlate with diabetic complications, especially microalbuminuria, retinal disease, neuropathy, and peripheral arterial disease[7]. Although the titers detected in diabetes are often lower than those typically seen in rheumatoid arthritis, even modest elevations may reflect significant immune activity. The consistently higher prevalence across diabetic populations implies that chronic hyperglycemia, oxidative stress, and metabolic inflammation create a physiological setting conducive to the development of autoantibodies such as RF[8].

3. Mechanisms Linking RF and Diabetes Mellitus

The association between rheumatoid factor and diabetes mellitus arises from a convergence of metabolic stress, immune dysregulation, and chronic inflammation[9]. Several interrelated mechanisms provide a plausible basis for RF production in individuals with either type 1 or type 2 diabetes, reflecting how metabolic disturbances can reshape immune function in ways that promote autoantibody formation.

3.1 Chronic Inflammation and B-Cell Activation

Persistent hyperglycemia induces oxidative stress and activates inflammatory pathways, leading to the release of cytokines such as interleukin-6, tumor necrosis factor-alpha, and interleukin-1 beta[10]. These cytokines create an immune-activating milieu that resembles low-grade autoimmune stimulation. B cells exposed to this environment undergo enhanced activation, immunoglobulin class switching, and increased autoantibody production, thereby facilitating the synthesis of RF[11]. This inflammatory state is not as localized or intense as that seen in classical autoimmune diseases, but its chronic nature contributes meaningfully to altered B-cell behavior and loss of tolerance.

3.2 Advanced Glycation End-Products and Neo-Antigen Formation

Sustained elevations in glucose accelerate the generation of advanced glycation end-products (AGEs) through non-enzymatic glycation of circulating and tissue proteins[12]. AGEs alter native protein structure, including that of IgG, producing modified epitopes capable of triggering immune recognition as non-self. These neo-antigens can stimulate autoreactive B cells, promoting the production of RF, particularly of the IgM isotype[13]. The accumulation of AGEs also enhances the inflammatory cascade, further reinforcing this autoantibody-generating loop.

3.3 Molecular Mimicry and Cross-Reactive Antigens

Individuals with poorly controlled diabetes often experience recurrent bacterial or fungal infections[14]. Persistent exposure to microbial antigens that share structural similarities with endogenous proteins may lead to the development of cross-reactive antibodies. Over time, this molecular mimicry can prime the immune system to generate RF, particularly when infections repeatedly activate pattern-recognition and B-cell pathways.

3.4 Defective Immune Regulation

Diabetes is associated with several abnormalities in immune regulation, including diminished regulatory T-cell activity, heightened Th1 and Th17 responses, and impaired checkpoints that normally maintain B-cell tolerance[15]. Such defects favor the survival and activation of autoreactive B cells capable of producing RF. These immune disturbances, though less overt than those in classic autoimmune disorders, nonetheless reflect a broader breakdown in self-tolerance[16].

3.5 Metabolic Inflammation

Metabolic inflammation, or metaflammation, is a hallmark of obesity-related type 2 diabetes[17]. Adipose tissue secretes pro-inflammatory adipokines such as leptin, resistin, and visfatin, which influence immune cell trafficking and activation. These signals enhance germinal center activity within lymphoid tissues, thereby increasing opportunities for autoantibody production, including RF. The interaction between metabolic stress and immune activation forms a self-amplifying cycle that can sustain RF positivity.

4. Clinical Significance of RF Positivity in Diabetes

RF positivity carries several clinical implications in the diabetic population, reflecting broader inflammation, metabolic instability, and increased risk of complications[18].

4.1 RF as a Marker of Systemic Inflammation

RF correlates strongly with markers of systemic inflammation, including C-reactive protein, erythrocyte sedimentation rate, and circulating pro-inflammatory cytokines[19]. In diabetes, where chronic inflammation contributes significantly to vascular injury and metabolic deterioration, RF may function as an indicator of heightened inflammatory burden.

4.2 RF and Cardiovascular Risk

RF has been linked to several markers of cardiovascular dysfunction, including increased carotid intima-media thickness, impaired endothelial reactivity, arterial stiffness, and a higher incidence of ischemic heart disease[20]. Immune complexes containing RF can deposit within the vasculature, activating complement pathways and promoting endothelial injury. In the context of diabetes, which inherently increases vascular fragility, RF may intensify cardiovascular risk.

4.3 RF and Glycemic Control

RF-positive individuals often demonstrate poorer metabolic outcomes, including elevated HbA1c levels, worsening insulin resistance, and accelerated beta-cell dysfunction[21]. These associations suggest that the inflammatory processes contributing to RF production may also interfere with glucose regulation and insulin signaling pathways.

4.4 RF and Diabetic Complications

RF positivity has been associated with several major complications of diabetes[22]. In diabetic retinopathy, RF may reflect or promote immune-complex–mediated microvascular injury that accelerates progression. In nephropathy, RF correlates with the severity of albuminuria, potentially indicating glomerular immune activation. In diabetic neuropathy, systemic inflammation associated with RF may worsen nerve ischemia and oxidative injury[23]. Additionally, individuals with elevated RF appear more prone to chronic foot ulcers and delayed wound healing, likely due to immune dysfunction and impaired tissue repair[24]. Overall, RF represents not merely an incidental finding but a potential marker of broader metabolic and immunologic stress in diabetes.

5. Potential Biomarker Applications

Rheumatoid factor is increasingly viewed as a potential biomarker that extends beyond its classical use in rheumatology[25]. In the context of diabetes, its relevance lies in its association with systemic inflammation, vascular injury, and immune activation. As research deepens, RF may become part of a broader panel used to stratify risk, monitor therapeutic response, and identify subgroups of diabetic patients with heightened inflammatory activity[26]. The versatility of RF as a measurable serologic marker makes it attractive for both clinical practice and research applications.

5.1 Predictor of Complications

RF has shown promise as a prognostic tool for identifying diabetic patients who may develop microvascular or macrovascular complications earlier than expected[27]. Elevated RF levels may indicate a higher likelihood of retinopathy progression as immune-mediated mechanisms contribute to microvascular damage in the retina. Similarly, RF has been associated with the onset and worsening of diabetic nephropathy, potentially through immune-complex deposition or inflammatory glomerular injury[28]. In macrovascular disease, RF may predict accelerated atherosclerosis, reflecting chronic immune activation that compounds metabolic risk factors. Identifying such high-risk individuals could support earlier interventions and enhanced monitoring strategies.

5.2 Marker of Immune Activation in Diabetes Trials

Given that many emerging diabetes therapies exert anti-inflammatory effects, RF could serve as an adjunct marker for assessing immunologic response in clinical trials[29]. Treatments such as interleukin-1 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists have demonstrated the ability to modulate inflammatory pathways. Monitoring RF levels alongside established markers such as C-reactive protein or cytokine profiles may provide a more nuanced understanding of how these interventions influence immune status[30]. This is particularly relevant as diabetes management increasingly incorporates approaches that target both metabolism and inflammation.

5.3 RF as a Marker in Diabetic Cardiomyopathy

Preliminary evidence suggests a potential role for RF in identifying individuals at risk for diabetic cardiomyopathy[31]. Myocardial inflammation and fibrosis, common features of diabetic cardiac remodeling, may correlate with elevated RF levels. Although this area remains under investigation, incorporating RF into cardiac risk assessment models could improve early detection of subclinical myocardial injury[32].

6. Therapeutic Implications

Beyond its utility as a biomarker, RF may also reflect therapeutically modifiable pathways [34]. Interventions that reduce systemic inflammation or oxidative stress may lower RF levels, offering insights into disease mechanisms as well as treatment response.

6.1 Anti-Inflammatory Approaches

Several antidiabetic and cardiometabolic agents exert anti-inflammatory effects that may indirectly reduce RF production[35]. Metformin, widely recognized for its immunomodulatory properties, suppresses pro-inflammatory signaling and may help normalize B-cell activity. GLP-1 receptor agonists decrease circulating inflammatory cytokines and improve endothelial function, potentially reducing RF-associated vascular injury[36]. SGLT2 inhibitors improve oxidative stress, reduce inflammation, and modulate immune cell metabolism, creating conditions less favorable for autoantibody production.

6.2 Antioxidant Strategies

AGE formation contributes to the generation of RF by creating neo-antigens through protein glycation. Antioxidants such as alpha-lipoic acid, vitamin E, and N-acetylcysteine can reduce oxidative stress and limit AGE accumulation, which may in turn diminish stimuli for RF induction[37]. This therapeutic avenue is particularly relevant in patients with high oxidative burden or poorly controlled hyperglycemia.

6.3 Immunomodulation

In severe inflammatory states or in individuals with autoimmune clustering, targeted immunomodulatory therapies may unintentionally reduce RF titers. Low-dose methotrexate, used for cardiovascular inflammation in selected populations, demonstrates such an effect by dampening inflammatory pathways and altering B-cell activation[38]. Although routine use of immunosuppressive therapy solely to modify RF levels is not justified in diabetes, these observations highlight the interconnected nature of metabolic inflammation and autoimmunity.

CONCLUSION

Rheumatoid factor, long regarded as a serologic marker of rheumatoid arthritis, has broader significance extending into metabolic disease. In diabetes mellitus, RF reflects persistent immune activation, oxidative stress, AGE-driven neoantigen formation, and B-cell dysregulation. RF positivity correlates with poor metabolic control, cardiovascular risk, and progression of diabetic complications. While not yet integrated into routine diabetes management, RF offers promise as a biomarker for identifying high-risk individuals and understanding the immunologic landscape of diabetes. As research advances, RF may become a clinically relevant tool in immunometabolic medicine.

REFERENCES

1. Ibiam, U. A., Orji, O. U., Aja, P. M., Ezeani, N. N., Ugwu, O. P. C. and Ekpono, E. U. Anti-Inflammatory Effects of *Buchholzia coriacea* Ethanol Leaf-Extract and Fractions in Freund's Adjuvant-Induced Rheumatoid Arthritic Albino Rats. *Indo American Journal of Pharmaceutical Sciences (IAJPS)*. 2018;**5** (7): 6341- 6357. https://doi.org/10.5281/zenodo.1311167.
2. Aloke, C., Ibiam, U. A., Obasi, N. A., Orji, O. U., Ezeani, N. N., Aja, P. M. and Mordi, J. C. Effect of ethanol and aqueous extracts of seed pod of Copaifera salikounda (Heckel) on complete Freund's adjuvant-induced rheumatoid arthritis in rats. J Food Biochem. 2019 Jul;43(7):e12912. doi: 10.1111/jfbc.12912. Epub 2019 May 23. PMID: 31353723.
3. Togashi T, Ishihara R, Watanabe R, Shiomi M, Yano Y, Fujisawa Y, Katsushima M, Fukumoto K, Yamada S, Hashimoto M. Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis. J Clin Med. 2025 Feb 25;14(5):1529. doi: 10.3390/jcm14051529.
4. Alum, E. U., Ibiam, U. A., Ugwuja, E. I., Aja, P. M., Igwenyi, I. O., et al. Antioxidant Effect of *Buchholzia coriacea* Ethanol Leaf Extract and Fractions on Freund's Adjuvant-induced Arthritis in Albino Rats: A Comparative Study. *Slovenian Veterinary Research*. 2022; 59 (1): 31–45. doi: 10.26873/svr-1150-2022.
5. Oguntibeju OO. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019 Jun 15;11(3):45-63.
6. Ezeani, N. N., Ibiam, U.A., Orji, O.U., Aja, P. M., Alum, E. U. and Offor, C. E. (2018). Effects of Aqueous and Ethanol Root Extracts of *Rauwolfia vomitori* on Inflammatory Parameters in Complete Freund's Adjuvant-Collagen Type II Induced Arthritic Albino Rat. *The Pharmaceutical and Chemical Journal*, **5** (2):72-83.
7. Luk AOY, Fan Y, Fan B, Chow EWK, O TCK. Heterogeneity in the development of diabetes-related complications: narrative review of the roles of ancestry and geographical determinants. Diabetologia. 2025 Nov;68(11):2386-2404. doi: 10.1007/s00125-025-06482-8.
8. Młynarska E, Czarnik W, Dzieża N, Jędraszak W, Majchrowicz G, Prusinowski F, Stabrawa M, Rysz J, Franczyk B. Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. International Journal of Molecular Sciences. 2025; 26(3):1094. https://doi.org/10.3390/ijms26031094
9. Wang J, Liu C, Ye Z, Lin H, Chen L. Association between cardiovascular-kidney-metabolic health and rheumatoid arthritis prevalence: A cross-sectional study. Medicine (Baltimore). 2025 Jul 4;104(27):e43006. doi: 10.1097/MD.0000000000043006.
10. Uti DE, Atangwho IJ, Alum EU, Egba SI, Ugwu OPC, Ikechukwu GC. Natural Antidiabetic Agents: Current Evidence and Development Pathways from Medicinal Plants to Clinical use. Natural Product Communications. 2025;20(3). doi:10.1177/1934578x251323393
11. Asif R, Khalid A, Mercantepe T, Klisic A, Rafaqat S, Rafaqat S, Mercantepe F. Role of Interleukins in Type 1 and Type 2 Diabetes. Diagnostics. 2025; 15(15):1906. https://doi.org/10.3390/diagnostics15151906
12. Zhang Y, Zhang Z, Tu C, Chen X, He R. Advanced Glycation End Products in Disease Development and

Potential Interventions. Antioxidants (Basel). 2025 Apr 18;14(4):492. doi: 10.3390/antiox14040492.
13. Mota KO, de Vasconcelos CML, Kirshenbaum LA, Dhalla NS. The Role of Advanced Glycation End-Products in the Pathophysiology and Pharmacotherapy of Cardiovascular Disease. International Journal of Molecular Sciences. 2025; 26(15):7311. https://doi.org/10.3390/ijms26157311
14. Holt RIG, Cockram CS, Ma RCW, Luk AOY. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. Diabetologia. 2024 Jul;67(7):1168-1180. doi: 10.1007/s00125-024-06102-x. Epub 2024 Feb 20.
15. Zhou T, Hu Z, Yang S, Sun L, Yu Z, Wang G. Role of Adaptive and Innate Immunity in Type 2 Diabetes Mellitus. J Diabetes Res. 2018 Nov 8;2018:7457269. doi: 10.1155/2018/7457269.
16. Asif R, Khalid A, Mercantepe T, Klisic A, Rafaqat S, Rafaqat S, Mercantepe F. Role of Interleukins in Type 1 and Type 2 Diabetes. Diagnostics. 2025; 15(15):1906. https://doi.org/10.3390/diagnostics15151906
17. Mukherjee S, Kundu R, Vidaković M. Editorial: Metaflammation in obesity and diabetes. Front Endocrinol (Lausanne). 2025 Jan 16;15:1540999. doi: 10.3389/fendo.2024.1540999.
18. Tian Z, Mclaughlin J, Verma A, Chinoy H, Heald AH. The relationship between rheumatoid arthritis and diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Endocrinol Metab. 2021 Feb 19;10(2):125-131. doi: 10.1097/XCE.0000000000000244.
19. Harrison M. Erythrocyte sedimentation rate and C-reactive protein. Aust Prescr. 2015 Jun;38(3):93-4. doi: 10.18773/austprescr.2015.034.
20. Hansen L, Parker I, Sutliff RL, Platt MO, Gleason RL Jr. Endothelial dysfunction, arterial stiffening, and intima-media thickening in large arteries from HIV-1 transgenic mice. Ann Biomed Eng. 2013 Apr;41(4):682-93. doi: 10.1007/s10439-012-0702-5.
21. Barry S, Sheng E, Baker JF. Metabolic Consequences of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2025 Oct;77(10):1167-1174. doi: 10.1002/acr.25537.
22. Verma AK, Bhatt D, Goyal Y, Dev K, Beg MMA, Alsahli MA, Rahmani AH. Association of Rheumatoid Arthritis with Diabetic Comorbidity: Correlating Accelerated Insulin Resistance to Inflammatory Responses in Patients. J Multidiscip Healthc. 2021 Apr 12;14:809-820. doi: 10.2147/JMDH.S285469.
23. Erlandsson MC, Tuameh M, Jukic Huduti E, Silfverswärd ST, Pullerits R, Bokarewa MI. Clinical Significance of Diabetes-Mellitus-Associated Antibodies in Rheumatoid Arthritis. Cells. 2022; 11(22):3676. https://doi.org/10.3390/cells11223676
24. Dawi J, Tumanyan K, Tomas K, Misakyan Y, Gargaloyan A, Gonzalez E, Hammi M, Tomas S, Venketaraman V. Diabetic Foot Ulcers: Pathophysiology, Immune Dysregulation, and Emerging Therapeutic Strategies. Biomedicines. 2025 Apr 29;13(5):1076. doi: 10.3390/biomedicines13051076.
25. Alum, E. U., Ibiam, U. A. and Ugwu, O. P. C. A Comprehensive Review of Treatment Approaches and Perspectives for Management of Rheumatoid Arthritis. *INOSR Scientific Research*. 2023; 10(1):12-17. https://doi.org/10.59298/INOSRSR/2023/2.2.13322
26. Xue M, Wang H, Campos F, Jackson CJ, March L. Rheumatoid Arthritis: Biomarkers and the Latest Breakthroughs. International Journal of Molecular Sciences. 2025; 26(21):10594. https://doi.org/10.3390/ijms262110594
27. Sobhi N, Sadeghi-Bazargani Y, Mirzaei M, Abdollahi M, Jafarizadeh A, Pedrammehr S, Alizadehsani R, Tan RS, Islam SMS, Acharya UR. Artificial intelligence for early detection of diabetes mellitus complications via retinal imaging. J Diabetes Metab Disord. 2025 Apr 12;24(1):104. doi: 10.1007/s40200-025-01596-7.
28. Shariat-Madar Z, Mahdi F. Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus. Molecules. 2025; 30(22):4448. https://doi.org/10.3390/molecules30224448
29. Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, Tousoulis D. The Anti-Inflammatory Effect of Novel Antidiabetic Agents. Life (Basel). 2022 Nov 9;12(11):1829. doi: 10.3390/life12111829.
30. Araújo R, Ramalhete L, Von Rekowski CP, Fonseca TAH, Calado CRC, Bento L. Cytokine-Based Insights into Bloodstream Infections and Bacterial Gram Typing in ICU COVID-19 Patients. Metabolites. 2025 Mar 16;15(3):204. doi: 10.3390/metabo15030204.
31. Wei J, Zhao Y, Liang H, Du W, Wang L. Preliminary evidence for the presence of multiple forms of cell death in diabetes cardiomyopathy. Acta Pharm Sin B. 2022 Jan;12(1):1-17. doi: 10.1016/j.apsb.2021.08.026.
32. Ianoş RD, Cozma A, Lucaciu RL, Hangan AC, Negrean V, Mercea DC, Ciulei G, Pop C, Procopciuc LM. Role of Circulating Biomarkers in Diabetic Cardiomyopathy. Biomedicines. 2024; 12(9):2153. https://doi.org/10.3390/biomedicines12092153

33. Conti V, Corbi G, Costantino M, De Bellis E, Manzo V, Sellitto C, Stefanelli B, Colucci F, Filippelli A. Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics. Biomolecules. 2020 Dec 14;10(12):1672. doi: 10.3390/biom10121672.
34. Alum, E. U. and Ugwu, O. P. C. Nutritional Strategies for Rheumatoid Arthritis: Exploring Pathways to Better Management. *INOSR Scientific Research.* 2023; 10(1):18-26. https://doi.org/10.59298/INOSRSR/2023/3.2.47322
35. Balogh DB, Wagner LJ, Fekete A. An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. International Journal of Molecular Sciences. 2023; 24(9):7789. https://doi.org/10.3390/ijms24097789
36. Maciejczyk M, Żebrowska E, Nesterowicz M, Żendzian-Piotrowska M, Zalewska A. α-Lipoic Acid Strengthens the Antioxidant Barrier and Reduces Oxidative, Nitrosative, and Glycative Damage, as well as Inhibits Inflammation and Apoptosis in the Hypothalamus but Not in the Cerebral Cortex of Insulin-Resistant Rats. Oxid Med Cell Longev. 2022 Mar 29;2022:7450514. doi: 10.1155/2022/7450514.
37. Varesi A, Chirumbolo S, Campagnoli LIM, Pierella E, Piccini GB, Carrara A, Ricevuti G, Scassellati C, Bonvicini C, Pascale A. The Role of Antioxidants in the Interplay between Oxidative Stress and Senescence. Antioxidants (Basel). 2022 Jun 22;11(7):1224. doi: 10.3390/antiox11071224.
38. Mangoni AA, Sotgia S, Zinellu A, Carru C, Pintus G, Damiani G, Erre GL, Tommasi S. Methotrexate and cardiovascular prevention: an appraisal of the current evidence. Ther Adv Cardiovasc Dis. 2023 Jan-Dec;17:17539447231215213. doi: 10.1177/17539447231215213.

CITE AS: Mugo Moses H. (2026). Rheumatoid Factor Beyond Rheumatoid Arthritis: Metabolic and Immunologic Implications in Diabetes Mellitus. IAA Journal of Applied Sciences 14(1):6-11. https://doi.org/10.59298/IAAJAS/2026/141611